Alopecia: Causes, Symptoms, Treatment & Prevention

Alopecia means hair loss—not a single disease. Follicles cycle through anagen growth, brief catagen, and telogen rest before shedding (exogen). Disruption arrives through immune targeting of follicles as in alopecia areata, shortening of anagen miniaturisation in androgenetic alopecia, synchronous telogen shedding after systemic stress (telogen effluvium), traction injury, inflammatory scarring disorders, chemotherapy, nutritional deficiency, thyroid disease, infection, or drug effects.

Because many variants share the bedside complaint of thinning or bald patches, the nursing contribution is disciplined pattern recognition, reversible trigger removal when applicable, adherence support for dermatology-prescribed regimens such as topical corticosteroids under potency limits or clinician-directed intermittent systemic steroid bursts, and psychologically safe acknowledgement that distress is medically legitimate even when lesions are painless.

Use pattern first—this drives labs, urgency, and who answers the pager. Dermatology severity tools (such as SALT percentage for alopecia areata) quantify extent for staging therapy; your documentation of roughly how much scalp is bare accelerates specialty visits.

↔On a small screen, swipe or scroll sideways to see the full table.

Patients articulate increased hair on brushes, widening part-lines, bald spots, beard or lash gaps, itching, tenderness, burning trichodynia, visible scalp glare under lights, broken hairs at margins, or concern about camouflage concealment slipping through a shift.

Typical patterns

• Patchy autoimmune loss: sudden round areas with smooth skin—not scaly unless coincident seborrhoeic overlap.
• Diffuse shed: hands pull out resting telogens easily; positives on gentle hair pull amid heavy life stressors.
• Patterned thinning: slowly progressive forehead recession or crown thin spot in males; Ludwig-pattern central sparing in females.

Atypical or easy-to-dismiss cues

• Children masking psoriasis-scale plaques or tinea exposures—maintain fungal checks when scale, adenopathy, or itch dominate.
• Patients with inflammatory systemic lupus erythematosus may show discoid plaques plus scarring alopecia—not “cosmetic thinning only.”
• Postpartum or post-operative shedding may overshadow iron deficiency requiring ferrous sulfate replacement once diagnosed.

Red-flag features that escalate urgency

• Rapidly expanding patchy loss with pain, ulceration, or violaceous plaques—evaluate for infection, ulcerated tumours, or aggressive inflammatory scarring.
• Systemic fever, arthralgia, oral ulcers—autoimmune multisystem flare may parallel scalp activity.
• New scalp nodules alongside hair loss—image or refer promptly; do not attribute solely to benign alopecia without clinical exam.

Mechanisms range from antigen-driven cytotoxic T-cell attack against anagen follicles (alopecia areata) to circulating androgen miniaturisation of follicles with shortened growth phases (patterned thinning), synchronous telogen shedding after cytokine perturbation or hypothyroidism, mechanical follicular rupture under tension, cicatricial lymphocyte infiltrates destroying stem-cell niches, cytotoxic chemotherapy with anagen arrest, micronutrient lack, psychiatric depression-associated neglect of nutrition, or endocrine disturbances such as polycystic ovary syndrome–linked hyperandrogenemia.

Non-modifiable or structural contributors

• Familial androgen receptor sensitivity predisposing to patterned loss.
• Polygenic autoimmune diatheses clustering with vitiligo, thyroiditis, type 1 diabetes—document family history thoughtfully.

Modifiable or situational triggers

• Tight hairstyles, chemical relaxers, heat styling without recovery intervals.
• Crash dieting iron-poor diets or malabsorption states depressing ferritin despite normal hemoglobin windows.
• Drug culprits: anticoagulants, beta-blockers retinoids, some anticonvulsants—flag new-onset shedding after medication starts with pharmacist-collaborative review rather than blaming stress alone.

Clinical assessment

Map distribution (patchy frontal vertex marginal diffuse), onset tempo, hairdresser observations, camouflage reliance, menstrual or pregnancy context, rheumatic symptoms, dermatophyte exposure to children, and detailed medication timeline. Inspect for loss of follicular openings, erythematous plaques, pustules, or scale bridging to psoriasis or fungal disease. Gentle hair pull manoeuvres help quantify active shedding but interpret cautiously immediately after brushing.

Laboratory investigations

• Thyroid-stimulating hormone when diffuse shed, menstrual irregularity weight change, family thyroid disease, or bradycardia clusters.
• Ferritin (± iron indices) particularly with heavy menses restrictive diets post-bariatric surgery or pallor—even when hemoglobin still normal.
• Total or bioavailable testosterone / DHEAS when virilisation accompanies female pattern thinning—coordinate with clinician rather than reordering blindly.
• ANA or autoimmune serologies only when connective tissue features emerge—not routine isolated patch testing.

Imaging & procedures

Dermoscopy in clinic delineates AA yellow dots tapering shafts versus miniaturisation patterns of patterned loss. Dermatology performs scalp biopsy when cicatricial disease is plausible or diagnoses diverge—a nursing role is safeguarding samples scheduling and steroid-sparing perioperative counselling when tacrolimus or steroid bridges are contemplated.

↔On a small screen, swipe or scroll sideways to see the full table.

Follow local formulary pathways for topical steroid potency tiers and pregnancy restrictions.

↔On a small screen, swipe or scroll sideways to see the full table.

Therapy is subtype-specific: remove traction, normalise thyroid or iron, counsel through cosmetic lag, and reserve immunomodulators for dermatology when AA is extensive or disabling. Nurses reinforce application technique for topical therapies (including facial spill avoidance), adverse-event surveillance for systemic immunosuppression, contraception stewardship around teratogens, and documentation of lesion photography between visits.

First-line management

• Limited AA: high-potency topical steroids or intralesional corticosteroid injections spaced per clinic protocol (NHS hair-loss overview lists common modality categories).
• Patterned androgenetic loss (men): clinician-prescribed oral antiandrogen therapy (often finasteride) plus adherence coaching; topical minoxidil remains backbone though not catalogued internally—coach application spacing and stray facial hair monitoring.
• Diffuse telogen shedding: treat triggers; replace iron guided by ferritin thresholds from your regional guideline.

Second-line / specialist-directed

• Contact immunotherapy topical anthralin or phototherapy historically used—specialist-directed given irritation risk.
• Systemic prednisone pulse regimens intermittent for roaring AA flare—glycaemia mood infection surveillance during therapy.
• Oral JAK inhibitors approved in select jurisdictions for severe AA—risk evaluation infection labs pregnancy avoidance per dermatology playbook.
• Refractory widespread AA sometimes receives methotrexate-class immunosuppression off-label—hepatotoxicity and pregnancy REMS messaging stay nursing-relevant.

Special populations

• Pregnancy/lactation: avoid finasteride; topical therapies only as obstetrically cleared; counsel postpartum TE as common.
• Adolescents: emphasise psychological safety; involve caregivers for traction behaviour change.
• Transplant / biologic therapy patients: coordinate infection screening before escalating immunosuppressive hair regimens.

Structure each encounter around pattern → reversible triggers → safety-netting timetable → psychosocial check-in. Nurses in primary care infusion suites endocrine clinics or wards often spot hair loss incidentally—turn that glance into purposeful documentation linking to hairdresser-elicited timelines.

• Monitoring intervals: reassess shedding intensity at six to twelve weeks after trigger correction; autoimmune regimens deserve scheduled photography every visit when photography consented.
• Medication adherence: explain that cosmesis improves slowly—often three to six months for oral antiandrogen or minoxidil regimens—with hair shed sometimes preceding regrowth spikes.
• Drug interaction vigilance: concurrent potent topical hydrocortisone-class preparations on face or body raise atrophy/striae risk especially children—mark body maps.
• Referral triggers: >50% scalp loss rapid facial involvement children with psychological crisis or any cicatricial suspicion escalate within days to weeks aligned with BAD-style pathways referenced below.
• Psychological safeguarding: screen mood when patients verbalise camouflage avoidance; liaison psychiatry frameworks parallel depression screening policies already on your wards.

Clinical decision flow (shift schematic)

1. Patchy slick scalp without scale → cue dermatology same routine unless systemic crisis.
2. Diffuse shed + fatigue cold intolerance → thyroid blood test pathway.
3. Heavy menses pallor restless legs → ferritin-guided iron replenishment conversations.
4. High-tension style + marginal breakage → offload tension before discussing implants.

• Anxiety depression social withdrawal—even when hair loss labelled “cosmetic-only.”
• Permanent follicle loss once fibrosis replaces stem-cell niche.
• Iatrogenic thin skin steroid acne cataract risk systemic exposure from unsupervised occlusion.
• Missed visceral malignancy or connective tissue disease when only psychosomatic attribution charted despite objective scarring plaques.

Clinician-facing prevention emphasises hairstyle rotation minimizing tension nutritional adequacy micronutrient repletion adherence to oncology scalp cooling bundles when chemotherapy planned and early autoimmune therapy rather than delaying until universalis morphology appears.

AA often relapses spontaneously—yet limited patch disease enjoys higher regrowth probabilities than longstanding total scalp involvement according to prognosis factors summarised across reviews. Telogen effluvium typically self-limits nine to twelve months after trigger resolution whereas androgenetic alopecia persists yet may stabilise pharmacologically.

Head coverings & cultural humility

Before suggesting “just remove the braid,” ascertain religious workplace or identity meaning of hair coverings; culturally safe hairdresser referrals outperform generic advice pamphlets alone.

Chemotherapy education

Align oncology teaching with cold-cap availability scalp hygiene regimens and realistic timelines for diffuse regrowth so patients perceive nursing continuity—not disjointed tumour-only messaging.

Escalation triggers

• Scalp tenderness with purulent plaques or cervical lymphadenopathy and broken hairs—potential kerion or dissecting folliculitis.
• Diffuse hair loss concurrent with tachycardia weight loss proximal weakness—evaluate thyrotoxicosis beyond cosmetic framing.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of alopecia patterns (androgenetic, alopecia areata, telogen effluvium, scarring alopecia red flags), first-line therapies (topical minoxidil, finasteride, intralesional steroid, JAK inhibitors) and dermatology-referral triggers.